China SXT Pharmaceuticals, Inc. (SXTC) P/E Ratio History
Deep ValueTrading at -0.3x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2019–2025
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, China SXT Pharmaceuticals, Inc. (SXTC) trades at a price-to-earnings ratio of -0.3x, with a stock price of $2.23 and trailing twelve-month earnings per share of $-1.35.
The current P/E is 100% below its 5-year average of 817.6x. Over the past five years, SXTC's P/E has ranged from a low of 24.4x to a high of 2005.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, SXTC trades at a 101% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, SXTC trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SXTC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SXTC Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SXTC P/E vs Peers
Traditional Chinese medicine producers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $600M | 32.5 | - | +17% | |
| $113M | 27.0 | 6.31 | +16% | |
| $192B | 12.2Lowest | 0.59Best | +2% | |
| $143B | 18.5 | - | -4% | |
| $281B | 15.6 | 0.74 | +8% | |
| $182B | 23.7 | 8.07 | +88%Best | |
| $383B | 91.4 | - | -1% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SXTC Historical P/E Data (2019–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | - | $76.20 | $0.18 | 423.3x | -48% |
| FY2025 Q2 | Sep 30 2024 | $109.50 | $4.49 | 24.4x | -97% |
| FY2019 Q4 | Mar 31 2019 | $102300.00 | $51.02 | 2005.1x | +145% |
Average P/E for displayed period: 817.6x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SXTC — Frequently Asked Questions
Quick answers to the most common questions about buying SXTC stock.
What is SXTC's P/E ratio?
China SXT Pharmaceuticals, Inc. (SXTC) trailing twelve-month P/E ratio is -0.3x, based on TTM diluted EPS of $-1.35. The 5-year average P/E is 817.6x and the historical range spans 24.4x to 2005.1x.
Is SXTC stock overvalued or undervalued?
SXTC trades at -0.3x P/E, below its 5-year average of 817.6x. At the 0th percentile of its historical range (24.4x–2005.1x), the stock is priced at a discount to its own history.
Is SXTC stock expensive?
No, SXTC is not expensive on a historical basis. The current P/E of -0.3x is below the 5-year average of 817.6x and sits at the 0th percentile of its valuation range.
What is SXTC's historical P/E range?
Over the past 5 years, SXTC's P/E ratio has ranged from 24.4x to 2005.1x, with a median of 423.3x and an average of 817.6x. The current P/E of -0.3x places the stock at the 0th percentile of this range. Full historical data spans 2019–2025.
How does SXTC's P/E compare to the S&P 500?
SXTC trades at -0.3x P/E versus the S&P 500 median of 24.4x. The 101% discount to the market suggests lower growth expectations or perceived higher risk.
How does SXTC's valuation compare to Healthcare peers?
China SXT Pharmaceuticals, Inc. P/E of -0.3x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is SXTC's PEG ratio?
SXTC PEG ratio is N/A, based on a P/E of -0.3x and EPS growth of -129.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is SXTC's earnings yield?
SXTC earnings yield is N/A, the inverse of its -0.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.